Corneal neovascularization and biological therapy

Area of Science:

• Ophthalmology
• Angiogenesis Research
• Immunology

Background:

• Corneal avascularity is crucial for vision.
• Corneal neovascularization (NV) impairs vision and can result from inflammation, hypoxia, or trauma.
• Maintaining the cornea's avascular state involves a balance of pro- and antiangiogenic factors.

Purpose of the Study:

• To explore novel therapeutic strategies for corneal neovascularization (NV).
• To evaluate the efficacy of antibody-based biologics in treating corneal NV.
• To assess the potential of biologics in reducing ocular inflammation and neovascularization.

Main Methods:

• Investigating antibody-based biologics in experimental animal models and clinical trials.
• Testing biologics with specificity for Vascular Endothelial Growth Factor A (VEGF-A).
• Evaluating anti-tumor necrosis factor-α (TNF-α) microantibodies for therapeutic effects.

Main Results:

• Bevacizumab and ranibizumab, targeting VEGF-A, demonstrated effectiveness in reducing corneal NV.
• Anti-TNF-α microantibodies also showed efficacy in treating corneal neovascularization.
• These biologics effectively reduce blood and lymphatic vessel ingrowth into the cornea.

Conclusions:

• Antibody-based biologics represent a promising therapeutic avenue for corneal neovascularization (NV).
• Targeting VEGF-A and TNF-α can significantly inhibit pathological angiogenesis in the cornea.
• Further research and clinical trials are warranted to establish these treatments for ocular surface diseases.